Cargando...
Impact of obinutuzumab alone and in combination for follicular lymphoma
Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease is considered incurable in most patients. Thus, new therapies are needed not only for those in the relapsed/refractory setting, but also for initial treatment. Obinutuzumab (G, G...
Gardado en:
| Publicado en: | Blood Lymphat Cancer |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6467363/ https://ncbi.nlm.nih.gov/pubmed/31360086 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S114173 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|